Boundless Bio, Inc. (BOLD)
NASDAQ: BOLD · Real-Time Price · USD
1.440
-0.030 (-2.04%)
At close: Apr 28, 2026, 4:00 PM EDT
1.440
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Boundless Bio Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Boundless Bio stock have an average target of 4.00, with a low estimate of 3.00 and a high estimate of 5.00. The average target predicts an increase of 177.78% from the current stock price of 1.44.
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 11, 2025.
Analyst Ratings
The average analyst rating for Boundless Bio stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $4 | Strong Buy | Maintains | $5 → $4 | +177.78% | Aug 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $5 | Strong Buy | Initiates | $5 | +247.22% | Jun 2, 2025 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $15 → $3 | Buy → Hold | Downgrades | $15 → $3 | +108.33% | May 28, 2025 |
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Dec 13, 2024 |
| Leerink Partners | Leerink Partners | Buy Initiates $25 | Buy | Initiates | $25 | +1,636.11% | Apr 22, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.44
from -2.60
EPS Next Year
-1.31
from -2.44
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | n/a | n/a | |||
| Avg | n/a | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.32 | -0.91 | |||
| Avg | -2.44 | -1.31 | |||
| Low | -2.46 | -1.88 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.